Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1-LBA1, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA100-LBA100, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1000-LBA1000, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1003-LBA1003, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1006-LBA1006, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1007-LBA1007, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1008-LBA1008, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA101-LBA101, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1018-LBA1018, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA10509-LBA10509, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA12001-LBA12001, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA12002-LBA12002, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA12003-LBA12003, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA12008-LBA12008, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA1510-LBA1510, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA2-LBA2, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA2000-LBA2000, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA2007-LBA2007, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA3-LBA3, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA3500-LBA3500, June 2026.

Journal of Clinical Oncology, Volume 44, Issue 17_suppl, Page LBA3503-LBA3503, June 2026.

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy.

In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo.

Among patients with RET fusion–positive non–small-cell lung cancer, adjuvant selpercatinib led to longer event-free survival than placebo. Adverse events of grade 3 or higher included elevated liver-enzyme levels.

Current curative-intent management of high-risk localized prostate cancer (nonmetastatic prostate cancer with extraprostatic extension or seminal-vesicle invasion, a histologic Gleason score of ≥8 [on a scale from 6 to 10, with higher scores indicating more aggressive disease], or a serum prostate-specific antigen level of ≥20 ng per milliliter) involves either...

In patients with metastatic prostate cancer with gene alterations, talazoparib–enzalutamide led to better progression-free survival outcomes than placebo–enzalutamide but with more serious adverse events.

The treatment of advanced prostate cancer has undergone significant improvements, with two developments proven to be especially transformative. The first advance was the establishment of treatment intensification in patients with metastatic castration-sensitive prostate cancer (hereafter referred to as metastatic androgen pathway modulation–sensitive [APMS] disease, in accordance with the recently updated...

In relapsed multiple myeloma, teclistamab improved 18-month progression-free survival as compared with standard therapy. Grade 3 or 4 infections were common; antimicrobial prophylaxis and immune globulin support were recommended.

In NSCLC with EGFR exon 20 insertions, first-line sunvozertinib led to longer progression-free survival than chemotherapy. The most common adverse events of grade 3 or higher were elevated creatine kinase, diarrhea, and anemia.

The treatment landscape of multiple myeloma has undergone a profound transformation over the past two decades, driven by deeper insights into disease biology, refined patient stratification, the integration of new prognostic biomarkers, and sustained therapeutic innovation. Today, most patients receive proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies as frontline...

In HER2-positive gastroesophageal adenocarcinoma, progression-free survival was longer with zanidatamab plus chemotherapy, both with and without tislelizumab, than with trastuzumab plus chemotherapy.

Ugandan children with sickle cell anemia who received 10 years of hydroxyurea therapy had sustained laboratory and clinical benefits, improved growth, and few toxic effects.

Two patients with inborn errors of immunity and progressive multifocal leukoencephalopathy received polyomavirus-specific T cells, followed by allogeneic hematopoietic transplantation with good neurologic outcomes.

Among patients with traumatic hemorrhage, prehospital transfusion of whole blood did not result in lower 30-day mortality than transfusion of plasma or red cells. Outcomes did not differ according to the storage age of blood.

A 50-year-old woman was admitted to the hospital because of vaginal bleeding and anemia. She had a history of fibroids and 1 month of progressive thrombocytopenia. A diagnosis was made.

In this study involving persons with sickle cell disease, adenine base editing was used to target the promoters of HBG1 and HBG2 in autologous hematopoietic stem cells to increase fetal hemoglobin expression.

In a phase 1–2 study of daraxonrasib, treatment-related adverse events of grade 3 or higher occurred in 30% of patients with previously treated RAS-mutated pancreatic cancer, and up to 35% of patients had an objective response.

The administration recently announced a new payment model to align some Medicare Part B drug payments with international pricing benchmarks. Various factors could affect the model’s scope and impact.

The authors describe the scientific foundations of a phase 1–2 study of daraxonrasib to treat metastatic pancreatic ductal adenocarcinomas.

In a study involving 180 blood bags, use of a double-knot closure rather than the usual single knot prevented bacterial contamination. This strategy may reduce the risk of blood-product contamination in resource-limited settings.

Among patients with hemophilia A, the annualized rate of treated bleeding events with Mim8 was more than 96% lower than with on-demand therapy and more than 42% lower than with clotting factor prophylaxis.

Technological innovations in health care—including artificial intelligence (AI)—have rapidly transformed core components of oncology care. With public health-care systems under substantial financial strain, advancing digital technology has become a game-changing tool in modern oncology workflows. Such technology offers the potential for more precise, efficient, and cost-effective interventions and could help to revolutionise clinical trials, cancer diagnosis, treatment, and health outcomes; reduce waiting times; and ease pressure on health-care services.

Breast radiotherapy is an integral component of breast cancer care to reduce locoregional recurrence.1 Historically, radiotherapy was delivered daily in 25–30 fractions over 5–6 weeks. Radiobiological and technological advances have enabled hypofractionation: shorter courses with larger doses per fraction achieve similar tumour control while reducing late tissue effects through reduced total dose.2 This approach was established in the first generation breast hypofractionation trials,3,4 in which the 3-week regimen (40 Gy in 15 fractions or 42·5 Gy in 16 fractions) matched the tumour control of conventional fractionation with less late tissue effects.

Radioligand therapy, commonly referred to as peptide receptor radionuclide therapy (PRRT), is an established and effective treatment for patients with advanced gastroenteropancreatic neuroendocrine tumours who have progressive disease after previous systemic therapy.1 Treatment selection in patients with progressive advanced gastroenteropancreatic neuroendocrine tumours is multifactorial and guided by primary site, hormonal functionality, symptom burden related to tumour volume, extent of metastatic disease, histological grade, and patient preference.

The Lancet Oncology Commission on the cancer workforce1 presents a stark analysis of an impending global health catastrophe. The Commission projects a workforce shortage of nearly 100 million individuals by 2050. This shortage directly correlates with a widening survival gap between high-income countries (HICs) and low-income and middle-income countries (LMICs). By 2050, Africa's 5-year net survival rate could be nearly half that of HICs, a disparity directly linked to the lack of qualified health professionals.

The Lancet Oncology Commission on the cancer workforce1 makes a case that governments, funders, and policy makers can no longer ignore. It elegantly reframes workforce investment—not as a development aspiration but as an economic imperative. However, a compelling case and a complete one are not always the same thing.

The Lancet Oncology Commission on the cancer workforce1 arrives at a moment of mounting pressure on cancer systems worldwide. However, the workforce crisis is not only a question of numbers, it reflects deeper challenges in how care is organised, delivered, and experienced. Patients, families, and caregivers continue to describe systems that are fragmented, impersonal, and poorly equipped to care for the person beyond the disease. At the same time, burnout and moral injury among oncology professionals are rising, further deepening the workforce crisis.

Workforce disparities in cancer care represent one of the most profound and persistent inequities in global health, with low-income and middle-income countries (LMICs) bearing a disproportionate share of cancer mortality. While high-income countries (HIC) maintain a relatively high number of specialists involved in cancer care, many LMICs struggle with major shortages. This inequality is notably severe for diagnostic specialists, who are 15 times more prevalent in HICs than in low-income regions.

The Lancet Oncology Commission on the cancer workforce1 documents a global crisis in the cancer workforce defined by chronic undersupply, accelerating demand, and health systems increasingly unable to recruit and retain the specialists they need. The UK offers a pointed illustration of how domestic policy choices can compound this challenge.

The Lancet Oncology Commission on the cancer workforce1 is a timely and important examination of the future unmet need for cancer health professionals, and the devastating fiscal and human cost of inaction. In many settings, this crisis is not looming; it has already arrived.

Abdurrahman Hajeer and colleagues published findings from an observational study in which 708 948 cancers were estimated to have required brachytherapy across 185 countries in 2022 (3·8% of incident cases).1 Assuming 218 cases per centre annually, 2246 additional centres would be required by 2050. These findings highlight major inequities in access but do not determine priority setting for cancer control resources.

We read with great interest the OligoPanc consensus by Carl-Stephan Leonhardt and colleagues.1 We congratulate the authors on this landmark interdisciplinary work, which represents the first international effort to standardise the definition of oligometastatic pancreatic ductal adenocarcinoma, and will help harmonise future clinical trials.

We thank Hector Prudhomme and colleagues for their interest in our Article describing a consensus definition of oligometastatic pancreatic ductal adenocarcinoma.1 Para-aortic lymph nodes are an important site of metastasis in pancreatic ductal adenocarcinoma and were therefore explicitly addressed, both in the Delphi process and in vignette three. Although 27 (82%) of 33 respondents to vignette three considered it oligometastatic pancreatic ductal adenocarcinoma, only 32 (56%) of 57 in the Delphi consensus classified para-aortic lymph node metastasis as oligometastasis, thereby meaning that the predefined 75% or greater consensus threshold was not reached.

We read with interest the systematic review and meta-analysis by Alexander H R Varey and colleagues1 assessing the potential survival benefit of sentinel node biopsy (SNB). We also recognise author John F Thompson for a long and accomplished career that successfully established SNB as a routine part of melanoma diagnostics.

We thank Dirk J Grunhagen and colleagues for their interest in our systematic review. We agree that minimising bias is crucial in such studies. Although individual patient data were not available, the Review was rigorously conducted to minimise residual confounding and selection bias through careful study design and appropriate analyses.

Morgans AK, Haresh KP, Jievaltas M, et al. Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2026; 27: 614–24—In this Article, the third sentence of the last paragraph of the Results section should have read “The most common grade 3–4 adverse events were hypertension (19 [4%] of 445 patients who received darolutamide vs eight [4%] of 221 patients who received placebo), anaemia (14 [3%] vs eight [4%]), and aspartate aminotransferase increase (ten [2%] vs one [<1%]).” This correction has been made to the online version as of June 1, 2026.

Widder J, Bol GM, Simek I-M, et al. Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC–ESTRO OligoCare consortium. Lancet Oncol 2026; 27: e238–47—In this Policy Review, the table headings should have read “Frequency”. In the Declaration of interests section, statements have been corrected for Helena M Verkooijen and Luca Visani. These corrections have been made to the online version as of June 1, 2026.

Clinicians in England do not have the capacity or headspace to do the innovation needed to deliver the Government's National Cancer Plan, a think tank has warned.

In Thailand, particularly in the northern provinces of the country (eg, Chiang Mai), sustained air pollution, mainly due to persistent wildfires and burning of agricultural waste by farmers, has led to a thick cloud of grey haze and substantial exposure to PM2·5, triggering surges in pollution-related illnesses including cancer.

Almost a fifth of the US population are exposed to potentially cancer-causing nitrates through their drinking water, according to a recent analysis by the Environmental Working Group (EWG).

One in five cancer clinical trials in the USA fail due to insufficient patient enrolment, according to a report from the American Cancer Society Cancer Action Network. Recruitment challenges are pushing researchers overseas, where recruitment is often faster and less expensive, while many eligible US Americans—especially older adults, people from racially minoritised or minority ethnic populations, residents of low-income rural communities, and members of Indigenous communities—cannot afford to participate in potentially life-saving trials, largely because of travel expenses.

On April 27, 2026, US radiation oncologists visited Capitol Hill to tell legislators that the recent policy changes in Medicare have threatened the sustainability of community cancer clinics in the country, as latest data suggested significant economic distress across the field.

David Krug (University Hospital Schleswig-Holstein, Kiel, Germany) presented the first results from a randomised controlled trial showing a progression-free survival benefit from metastasis-directed therapy for patients with oligometastatic breast cancer. In the randomised controlled OLIGOMA trial, patients were randomly assigned to systemic therapy (n=44) or systemic therapy plus stereotactic body radiotherapy (SBRT) to metastatic lesions (n=43). Co-primary endpoints were progression-free survival and quality of life at 12 weeks.

Gaps in patient data reported to the US National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database by some rural, safety-net, and community hospitals could skew cancer rates and survival outcomes in studies of some of the most vulnerable patient populations. Patients treated at facilities not accredited by the American College of Surgeons Commission on Cancer were two to three times more likely to have missing clinical data in SEER patient records than those treated at Commission on Cancer-accredited centres, researchers reported.

Lung cancer is the leading cause of cancer deaths, causing approximately 1.8 million deaths worldwide.1 Screening with low-dose CT (LDCT) has been shown to significantly reduce lung cancer-specific mortality among populations at high-risk by 20–26%.2 National lung cancer screening programmes have been implemented in several countries and will be introduced in Germany in 2026. Despite these advances, population-level implementation fails to adequately reach those at highest risk;3 globally, lung cancer screening programmes face persistent challenges in achieving equitable access across racial, ethnic, geographic, and socioeconomic groups.

Aglatimagene plus valacyclovir was associated with longer disease-free survival than placebo plus valacyclovir when added to standard of radiotherapy for the treatment of localised prostate cancer, offering a meaningful benefit without increasing clinically significant toxicity.

Long-term follow-up confirms that 26 Gy in five fractions over 1 week is safe and efficacious for adjuvant radiotherapy to the breast or chest wall, supporting its use as a standard of care. Efficacy data for this schedule in the axillary nodal radiotherapy setting are reassuring; however, sample size limits precision of estimation for this subgroup on its own.

Using sunitinib as an internal control, our results show clinically significant antitumour efficacy of [177Lu]Lu-dota-tate in pretreated, progressive, somatostatin receptor-positive, metastatic pancreatic neuroendocrine tumours, and a better quality of life during the treatment phase. Late adverse events were reported in the [177Lu]Lu-dota-tate group that might affect the tolerance of subsequent lines of treatment.

Long-term follow-up supports the safety and local control of SABR for non-surgical patients with renal cell carcinoma, with no observed local recurrences or cancer-related deaths in this cohort, which had predominantly T1b disease or higher.

This pooled analysis from two clinical trials of SABR in patients with larger primary kidney tumours unsuitable for surgery supports evidence of long-term local control and low rate of severe adverse events. These results support further investigation through a randomised trial comparing SABR with surgery in select operable patients.

MRI-guided adaptation for glioblastoma enables margin de-escalation and resulted in a low rate of marginal failure. A randomised trial comparing this technique to a standard large-margin radiotherapy approach will establish whether toxicity and quality-of-life improvements can be realised.

The pandemic's greatest impact was during the first few months of societal lockdowns in 2020 when barriers in access to health care were greatest. Further research is needed to understand whether patients with a missed diagnosis were diagnosed at a later date and if they presented at a later stage.

This breast radiotherapy dosimetry audit shows the feasibility of high-quality large-scale, real-world dosimetric collection and evaluation across the NHS in England. Heart and lung doses predominantly met constraints and were comparable to international benchmarks. However, dosimetric variation existed between centres, particularly in volumetric-modulated arc therapy planning, identifying opportunities for quality improvement.

The shortage of well-trained personnel to deliver cancer care and conduct research remains a major obstacle to reducing disparities in cancer survival between high-income countries and low-income and middle-income countries (LMICs). This Commission set out to provide actionable guidance for strengthening the global cancer workforce with an emphasis on reducing these disparities. To better understand the extent of the rising global cancer burden and the resulting workforce needs, we modelled the current and future global landscape of 17 common cancers and 18 workforce personnel types.

Treatment of pediatric HCC and FLC remains challenging. The current results support risk‐stratification methods currently under study prospectively and the independent study of these tumors in the future.

TIPN was common and strongly predicted taxane dose reduction in Black patients. The FACT‐GOG/NTx 4‐item subscale performed best, supporting its use in future trials. Although early TIPN did not predict long‐term functional decline, persistent neuropathy adversely affected HRQOL, underscoring the importance of early identification and supportive care to improve dose delivery and equity in breast cancer outcomes.

Envafolimab combined with Rh‐endostatin demonstrated favorable efficacy and tolerable toxicity in patients with PD‐L1–positive, advanced driver‐gene negative NSCLC.

This study identified genetic ancestry–concordant ceramide metabolites that were associated with outcomes in patients with mCRPC who received treatment with ARPI from the Abi Race and PANTHER studies (ClinicalTrials.gov identifiers NCT01940276 and NCT03098836, respectively).

Cy‐JAK/STAT pathway mutations are uncommon in AML, but each mutation has distinct biologic and clinical characteristics. The worse survival observed in patients with JAK2‐mutated AML largely appeared to be driven by the co‐occurrence of high‐risk characteristics. Blast‐phase MPN was associated with a dismal prognosis.

Low testosterone at diagnosis does not appear to predict a reduced mortality risk when adding docetaxel to RT and ADT in otherwise healthy patients with nonmetastatic high‐risk PC, whereas normal testosterone does, which provides evidence to support testosterone group as a predictive biomarker.

May is a time to elevate mental health awareness. In the USA, May is designated as Mental Health Awareness Month; Europe marks Mental Health Week (May 4–8); and the UK observes Mental Health Awareness Week (May 11–17). These events invite a renewed collective focus on connection, resilience, and hope for the more than one billion people worldwide who live with mental health conditions, placing a substantial burden on individuals and health systems. Yet, our understanding of mental health within the fields of haematology and haematological oncology remains limited.

Since the year 2000, the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have authorised many novel cancer therapies based on phase 1–2 single-arm trials.1,2 Most of these were granted as conditional marketing authorisations (EMA) or Accelerated Approvals (FDA), which aim to provide early access to promising therapies in diseases with high unmet medical need. Acknowledging that single-arm trials can show biological activity but cannot reliably establish whether an experimental treatment is better than the current standard, these approvals are contingent on demonstration of clinical benefit in subsequent confirmatory randomised trials.

TikToks (short vertical videos) are increasingly infiltrating our lives, as well as those of our patients. In mid-2020, TikTok was one of the fastest growing social media platforms, with over half a billion active users and with TikToks also routinely viewed on other social media platforms or shared directly by friends and family. Armed with this knowledge, in my role as Director of the donor recruitment organisation Stem Cell Club, I led the development of a library of TikToks to engage young adults to stem-cell donation.

Clinical trials in multiple myeloma continue to fail populations most affected by the disease, with Black individuals remaining profoundly underrepresented in the studies that define contemporary treatment standards. Multiple myeloma is the second most common haematological malignancy, and the incidence, prevalence, and disability-adjusted life years attributable to the disease have increased over time, with mortality rates remaining high. Despite this burden, the therapeutic landscape of multiple myeloma has been transformed by the development of novel agents evaluated in clinical trials, resulting in substantial improvements in survival and meaningful gains in quality of life.

Very early PET-guided intensification with BrECADD yields high activity in advanced-stage classic Hodgkin lymphoma while sparing most patients intensive chemotherapy.

Pirtobrutinib was highly active and well tolerated, regardless of previous exposure to covalent BTK inhibitors, and might be a promising new therapeutic option for patients with relapsed or refractory Waldenström macroglobulinaemia, particularly in those previously exposed to covalent BTK inhibitors, for whom durable and effective treatments are needed.

Since the year 2000, early-phase trials in relapsed or refractory diffuse large B-cell lymphoma have shown more than a doubling of response rates, driven primarily by cellular and bispecific antibody therapies, while maintaining low treatment-related mortality. These results provide risk-benefit trends in early-phase trials and define contemporary benchmarks for clinicians, investigators and regulators.

In this setting, Peg-IFN combined with nilotinib induced higher initial rates of MR4·5 compared to TKI monotherapy, despite additional side effects. The onset of psychiatric events might promote immediate cease of Peg-IFN and psychiatrist advice Whether this early molecular response translates into sustained treatment-free survival should be studied in a randomised trial sufficiently powered for this outcome.

The development of novel T-cell redirecting immune therapies—including immune checkpoint inhibitors, bispecific antibodies, chimeric antigen receptor T cells, and virus-specific T cells—represents a major advancement in the treatment of haematological malignancies. Although such therapies have strong evidence for efficacy in the treatment of B-cell neoplasms, several unique challenges are encountered when using these therapies for the treatment of T-cell malignancies. In this Review, we discuss the application of T-cell modulating immune therapies in T-cell neoplasms, with a focus on the complicated bidirectional interactions between malignant and bystander T cells in disease pathogenesis, and the resultant challenges affecting the design and deliverability of T-cell modulating therapies in this cohort.

Autosomal dominant acute porphyrias are rare inherited disorders of haem biosynthesis characterised by accumulation of potentially neurotoxic porphyrin precursors and attacks of severe abdominal pain with autonomic and neuropsychiatric features. Disease severity ranges from asymptomatic individuals to those with recurrent, life-threatening attacks. The International Porphyria Network invited 34 acute porphyria specialists from 17 countries to form an expert panel. The invited group included clinicians from diverse specialities (ie, internal medicine, haematology, endocrinology, gastroenterology, hepatology, neurology, and biochemistry), together with laboratory scientists and patient representatives.

A 69-year-old woman was referred to our department after monoclonal gammopathy was detected during routine testing. Her medical history included dyslipidaemia, hypothyroidism, and right hip replacement due to congenital dysplasia. Physical examination, complete blood count, and serum biochemical tests were unremarkable. Immunofixation revealed monoclonal IgGλ (total IgG 1060 mg/dL), with a normal free light chain (FLC) ratio. Urine immunofixation was negative. A bone marrow biopsy showed 12% clonal plasma cell infiltration, consistent with smouldering multiple myeloma (SMM) pending whole-body, low-dose CT (WBLD–CT).

A 67-year-old woman was diagnosed with nodal marginal zone lymphoma with IgMκ paraproteinaemia, circulating monoclonal B cells, multifocal lymph node involvement (MYD88WT), and splenomegaly. Rituximab monotherapy yielded partial metabolic remission on PET–CT and an IgM concentration decrease from 15·4 g/L to 12·4 g/L (normal range: 0·4–2·3 g/L). However, the patient reported severe progressive diarrhoea (up to 50 times per day). A 13 kg weight loss resulted in total parenteral nutrition dependence.

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is caused by transplacental passage of maternal antiplatelet antibodies and severely affects approximately 1 in 1000 births. Zhang and colleagues probed the structure-function relationships underpinning interactions of alloantibodies against the most common target, human platelet antigen 1a (HPA-1a). Their data in this Plenary Paper help explain why some alloantibodies cause severe hemorrhagic FNAIT while others result in milder, asymptomatic thrombocytopenia.

No disease better exemplifies how the science of hematology transforms care and outcomes for a disease than thrombotic thrombocytopenic purpura (TTP). Scully, Carter, and Subhan review how a feared syndrome of idiopathic, acute multiorgan failure in the presence of microangiopathic hemolytic anemia came to be recognized as a deficiency of ADAMTS13 25 years ago, paving the way for high-resolution understanding of pathogenesis and multiple targeted treatment modalities enabling precision therapy. They also identify ongoing questions guiding current trials for both acquired and congenital TTP.

Hemophagocytic lymphohistiocytosis (HLH)–like manifestations after chimeric antigen receptor T-cell therapy, now referred to as immune effector cell–associated HLH-like syndrome and high-grade cytokine release syndrome (CRS) with HLH-like multiorgan dysfunction, are increasingly recognized, and their management is evolving. Johnson and colleagues use 2 illustrative cases to outline their practical approach to these major clinical challenges. They emphasize early identification, use of anticytokine therapy with either emapalumab or ruxolitinib when organ toxicities worsen despite conventional CRS-directed treatment, and the need for ancillary supportive care as central to success.

While graft-versus-leukemia activity is the major therapeutic advantage of allogeneic hematopoietic stem cell transplantation (HCT), clearance of leukemia pre-HCT improves outcomes and may improve engraftment. The humanized anti-CD117 antibody briquilimab disrupts critical stem cell factor–CD117 signaling to normal and leukemic stem cells. Muffly et al report a phase 1 trial studying the addition of briquilimab prior to nonmyeloablative conditioning in patients with acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS), demonstrating major reductions in leukemic stem cells, minimal toxicity, and encouraging but preliminary posttransplant outcomes. Such precision conditioning approaches warrant further clinical investigation.

Neither current mutational nor transcriptional profiling of bulk lymphoma biopsies explains why some cases of diffuse large B-cell lymphoma (DLBCL) are resistant to standard therapy. To discover the molecular identity of chemotherapy-tolerant persister cell populations, Li et al longitudinally profiled DLBCL samples from patients who prove to have refractory or relapsing disease. These are less differentiated cells, akin to memory B cells, and their enhanced stemness is dependent on upregulated casein kinase 1ε (CSNK1E). These and other emerging data provide new avenues for elimination of relapse-initiating residual lymphoma.

Although this is not apparent by standard microscopy, the bone marrow has functionally distinct areas where external signals govern stem cell behavior. It is postulated that these are disrupted in leukemias. Li and colleagues used high-resolution imaging and a murine model of BCR::ABL1⁺ blast-phase chronic myeloid leukemia (CML) to map the extent of leukemia-induced changes in the bone marrow microenvironment. They show leukemia-induced remodeling creating immune-privileged niches through T-cell exhaustion, as well as vascular abnormalities that fail to support normal hematopoeisis, refining our knowledge of how leukemia overwhelms normal marrow function.

The zinc finger transcription factor GATA1 is a master regulator of erythropoiesis, coordinating the differentiation program. In some conditions such as Diamond-Blackfan anemia and associated with some mutations in Down syndrome, a short form of GATA1 is dominant. Ling and colleagues define the function of this isoform, demonstrating in primary erythroid cells how it can reprogram metabolism through its regulation of PKM, the gene encoding pyruvate kinase M1/2.

New England Journal of Medicine, Volume 394, Issue 20, Page 2015-2025, May 28, 2026.

New England Journal of Medicine, Volume 394, Issue 20, Page 1991-2001, May 28, 2026.

New England Journal of Medicine, Volume 394, Issue 20, Page 2002-2014, May 28, 2026.

New England Journal of Medicine, Volume 394, Issue 20, Page 1979-1990, May 28, 2026.

New England Journal of Medicine, Volume 394, Issue 20, Page 2064-2066, May 28, 2026.

New England Journal of Medicine, Volume 394, Issue 20, Page 2066-2070, May 28, 2026.

New England Journal of Medicine, Volume 394, Issue 20, Page 2061-2064, May 28, 2026.

New England Journal of Medicine, Volume 394, Issue 20, Page 2059-2061, May 28, 2026.

New England Journal of Medicine, Volume 394, Issue 20, Page 2054-2055, May 28, 2026.

New England Journal of Medicine, Volume 394, Issue 20, Page 2064-2064, May 28, 2026.

New England Journal of Medicine, Volume 394, Issue 20, May 28, 2026.

New England Journal of Medicine, Volume 394, Issue 20, May 28, 2026.

New England Journal of Medicine, Volume 394, Issue 20, May 28, 2026.

New England Journal of Medicine, Volume 394, Issue 20, May 28, 2026.

New England Journal of Medicine, Volume 394, Issue 20, Page 1971-1973, May 28, 2026.

New England Journal of Medicine, Volume 394, Issue 20, Page 1974-1976, May 28, 2026.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

Radiation‑induced musculoskeletal toxicities are one of the major limitations in pediatric patients whose skeletons are still developing. FLASH radiotherapy, delivered at ultra-high dose rates (>40 Gy/s), has demonstrated normal tissue sparing in preclinical models, but its effects on the developing skeleton and marrow remain incompletely characterized. This study evaluated the normal-tissue effects 10 weeks after proton FLASH irradiation in juvenile mice, modeling the pediatric context.

Cardiac stereotactic body radiotherapy (SBRT) offers a noninvasive alternative to the conventional radiofrequency (RF) catheter ablation for treating refractory ventricular tachycardia (VT) in patients who are poor candidates for ablation procedures. However, accurate target delineation remains challenging due to limited scar visualization on CT and implanted cardioverter-defibrillator (ICD)-related MRI artifacts. We developed and evaluated a 3D wideband (WB) late gadolinium-enhanced (LGE) MRI protocol for artifact suppression, geometric accuracy, and scar delineation in SBRT planning.

Radiosurgical treatment of multiple intracranial targets using a single isocenter is more efficient than sequential isocenter treatment. The primary concern with single-isocenter, multitarget (SIMT) stereotactic radiosurgery (SRS) is that rotational error may cause underdosing of peripheral lesions and/or increased normal tissue toxicity, particularly for targets distant from the isocenter. Many centers mitigate this risk by adding a planning target volume (PTV) margin, which increases dose to normal brain tissue.

Grade 2 and 3 late xerostomia is a chronic, debilitating complication of radiation therapy for head and neck cancers. We assessed the safety and efficacy of AAV2-hAQP1 gene therapy as a treatment for this condition.

Advances in radiation (RT) treatment planning enhance the need for uniform quality oversight on clinical trials. NRG GY-017 was a randomized trial of the anti PD-L1 antibody, atezolizumab, before and concurrent (Arm A) or concurrent with CRT (Arm B) for locally advanced cervical cancer. We describe the prospectively collected pre-treatment RT quality and workflow.

The role of stereotactic ablative radiotherapy (SABR) in head and neck cancer remains uncertain. Historically used mainly for re-irradiation, its application in other clinical scenarios has expanded with recent advances.

FLASH radiotherapy shows promise in reducing normal tissue toxicity compared to conventional radiotherapy. Although several studies report skin-sparing effects of FLASH, few have quantitatively assessed this effect or explored underlying immunological mechanisms.

Radiation pneumonitis (RP) is a dose-limiting toxicity in lung cancer radiotherapy, often poorly predicted by static clinical and dosimetric models. We aimed to identify a robust, blood-based proteomic signature grounded in the longitudinal biological response to radiation to enable accurate, early risk stratification.

Recently, results from NRG/RTOG 0924, the largest randomized trial to evaluate the benefit of whole-pelvic radiotherapy (WPRT) in localized prostate cancer, were presented. We conducted an aggregate meta-analysis of all phase III randomized trials to determine the impact of WPRT on oncologic outcomes.

Optimal management of large, unresectable hepatocellular carcinoma (HCC) remains uncertain. Proton beam therapy (PBT) offers dosimetric advantages for sparing normal liver. Clinical outcomes for these patients in Western populations are limited. This study evaluated clinical outcomes, toxicity, and patterns of failure among Western patients with large localized HCC treated with PBT.

Advances in neoadjuvant chemotherapy (NAC) have markedly increased pathologic complete response (pCR) rates in breast cancer, prompting reevaluation of the need for adjuvant radiotherapy (RT) in patients with excellent treatment response. The NSABP B-51 trial showed no survival benefit from regional nodal irradiation in patients achieving nodal pCR after NAC; whole-breast RT was still routinely delivered irrespective of breast response. Thus, the potential to safely omit RT in patients achieving breast pCR remains uncertain.

To evaluate in a meta-analysis the efficacy of external beam radiotherapy (EBRT) with immunotherapy (IO) in hepatobiliary malignancies, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), and identify factors associated with improved treatment response.

To report long-term toxicity and disease outcomes from a randomized trial comparing passive-scattering proton therapy (PSPT) and intensity-modulated photon radiotherapy (IMRT), both with concurrent chemotherapy, for non-small-cell lung cancer (NSCLC).

Cervical cancer is the fourth most common cancer among women worldwide [1,2] with over 600,000 new cases and over 300,000 deaths annually [3]. The burden is disproportionately higher among women in low- and middle-income countries (LMICs), where more than 85% of cervical cancer-related deaths occur due to limited access to screening, Human Papillomavirus (HPV) vaccination, other HPV prevention strategies [3,4]. The global prevalence of cervical cancer is projected to increase by 14–17% by 2030 if no intervention is made to increase the availability of screening and protective vaccinations [5].

Census-based surrogates such as patients on treatment, fractions delivered, and course length have traditionally been used to assess radiation oncology departmental performance. These measures may no longer capture the complexities of modern radiotherapy, given the increased adoption of hypofractionation and stereotactic techniques. This study analyzes longitudinal trends in clinical operations, including treatment modalities, fractionation patterns, and financial performance, to identify value-based departmental performance metrics.

Configuring clinical linear accelerators (linacs) for ultra-high dose rate (UHDR) electron experiments typically requires invasive hardware manipulation and/or irreversible modifications, limiting broader implementation. This work reports a reversible and non-invasive UHDR electron configuration of a clinical TrueBeam linac that enables switching between preclinical UHDR and conventional clinical treatment (CONV) modes through software settings, without accessing the linac interior.

In analyses from the phase III ARANOTE trial reported in The Lancet Oncology, Morgans et al found that darolutamide was associated with prolonged times to worsening pain and worsening health-related quality of life (QOL) compared with placebo in patients with metastatic hormone-sensitive prostate...

As reported in The Lancet Oncology by Pfob et al, a pooled analysis of randomized trials showed that performance of lymph node surgery for the sole purpose of determining eligibility for CDK4/6 inhibitor treatment does not appear to be a promising strategy in patients with early breast cancer.

ASCO has announced a collaboration with Ryght AI aimed at accelerating the identification and activation of research sites for the CDK4/6 Inhibitor Dosing Knowledge (CDK) Study, a clinical trial evaluating different starting doses of CDK4/6 inhibitors in patients with metastatic breast cancer. The...

The ASCO Annual Meeting is one of the largest and most impactful oncology conferences of the year, featuring practice-changing data, state-of-the-art updates, developmental therapeutics, global issues, and more.

The EGFR-targeting tyrosine kinase inhibitor sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations (EGFR exon20ins).

On May 28, 2026, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor durvalumab (Imfinzi) in combination with bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC).

Local radiotherapy may help control disease spread in patients with oligometastatic breast cancer, according to findings from the OLIGOMA trial presented during the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026; Abstract 5611). 

The ECOG-ACRIN Cancer Research Group, in collaboration with the SWOG Cancer Research Network, has launched a new initiative to analyze paired original and recurrent tumor specimens from two practice-changing breast cancer clinical trials. Through the translational study EA1241, researchers will...

Two larger doses of radiotherapy for prostate cancer caused no additional side effects compared to the standard five doses of radiotherapy, according to results from the HERMES trial presented at the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026). Experts say the...

On May 27, the U.S. Food and Drug Administration (FDA) approved pivekimab sunirine-pvzy (Decnupaz), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

CB-011, the first allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell therapy incorporating immune cloaking, achieved a high overall response rate in heavily pretreated patients with relapsed or refractory multiple myeloma in the phase I CaMMouflage trial. Dose-escalation results were...

On May 13, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sonrotoclax (Beqalzi), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.

Select patients with early-stage breast cancer who achieved exceptional responses to ablative radiation therapy and endocrine therapy were able to omit surgery without disease progression, according to findings from a prospective phase II trial presented during the Congress of the European Society...

In a phase II trial (COMRADE) reported in the Journal of Clinical Oncology, McKay et al found that the addition of olaparib to radium-223 improved radiographic progression–free survival in men with castration-resistant prostate cancer and bone metastases.

In a retrospective cohort study reported in JAMA Network Open, Tatum et al found that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was associated with reduced risk of all-cause mortality in patients with breast cancer and obesity or type 2 diabetes (T2D).

Final results from a landmark European Organisation for Research and Treatment of Cancer (EORTC) randomized trial with more than 20 years of follow-up have shown that irradiation of the internal mammary and medial supraclavicular (IM-MS) lymph nodes reduces breast cancer mortality but does not...

Individuals who gain the highest amounts of weight in adulthood are at significantly greater risk for developing certain obesity-related cancers, according to findings from a pooled cohort study presented at the European Congress on Obesity 2026 (Abstract 0759; AD16.04). The findings were also...

Investigators used data from the Surveillance, Epidemiology, and End Results (SEER) database to analyze trends in multiple myeloma mortality in the United States from 1975 to 2023. Their findings were published in Oncotarget.

On May 22, the U.S. Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk (Datroway), an antibody-drug conjugate targeting trophoblast cell surface antigen 2 (TROP2), for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for ...

In two complementary preclinical studies published in Blood, investigators reported that mezigdomide, a cereblon E3 ligase modulator, may help overcome T-cell dysfunction in multiple myeloma, thereby enhancing the activity of BCMA-directed CAR T-cell and bispecific T-cell engager therapies. These...

A new study has shown that AI avatar–based digital patient engagement prior to in-person radiation treatment consultations may enable patients to feel more knowledgeable and less stressed than patients who did not engage with an AI avatar, according to findings presented during the Congress of the...

Short-term fasting before and after chemotherapy reduced insulin levels and was associated with improved treatment response in patients with high-grade serous ovarian cancer, according to results from a two-arm pilot randomized trial that will be presented by Marchetti at the 2026 ASCO Annual...

A 4-week structured yoga intervention improved overall mood disturbance, anxiety, and fatigue among cancer survivors, according to findings from a phase III randomized controlled trial that will be presented at the 2026 ASCO Annual Meeting (Abstract 12004). The analysis also suggested that...

Patients with advanced prostate cancer treated with darolutamide experienced significantly less objectively assessed cognitive decline over 24 weeks than those receiving enzalutamide, according to results from the prospective, randomized open-label phase II ARACOG (AFT-47) trial to be presented at...

Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known.

A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort.

All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators.

In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock.

Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP.

The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system.

NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs.

Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source.

A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care.

To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care.

Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success.

Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC).

Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery.

In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU.

Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening.

Ibrutinib improves overall survival in patients with mantle cell lymphoma

First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2⁺ GEA

Kidney injury molecule-1 (KIM-1) is overexpressed in renal cell carcinoma (RCC), and consistent shedding of this cell-surface protein into the circulation makes it a promising blood-based biomarker for this disease. Herein, we outline potential roles of circulating KIM-1 in diagnosis, prognostication and therapeutic monitoring of RCC, as well as research priorities for clinical translation of this biomarker.

The management of gastro-oesophageal adenocarcinoma (GEA) is undergoing substantial changes owing to evolving treatment paradigms and new therapeutic strategies on the background of a shifting global epidemiology. This Review discusses the state-of-the-art perioperative management of resectable GEA, with an emphasis on how biological heterogeneity influences geographical practice patterns, and outlines future directions for research including precision medicine approaches, biomarker-guided immunotherapy and tailored surgical approaches.

Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer

On 3 February 2026, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act was enacted, enabling Medicare coverage for multi-cancer early detection (MCED) tests. This legislation coincides with new results from key clinical trials and has important implications for payers and policymakers, given the lack of FDA approval of any MCED test or evidence that population screening with such tests reduces cancer-related or all-cause mortality.

The historical development of plasma Epstein–Barr virus DNA for informing clinical decisions for patients with nasopharyngeal carcinoma has culminated in the EP-STAR trial. The circulating tumour DNA clearance patterns observed during neoadjuvant chemotherapy could be used to guide adjuvant therapy, improve outcomes and possibly reflect differences in tumour biology. Herein we discuss why this study constitutes a full-circle moment and provides valuable insights for advancing circulating tumour DNA-based applications in precision oncology.

Spinal metastases are associated with debilitating pain and neurological deterioration as well as a poor prognosis and have historically been managed with a palliative intent. Now, following the emergence of stereotactic body radiotherapy (SBRT), more effective pain control as well as control of the metastatic lesions is becoming feasible. In this Review, the authors describe the development and role of SBRT in the management of spinal metastases.

Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 621-628, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 629-636, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 637-644, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 645-655, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 656-665, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 666-672, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 673-684, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 685-695, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 696-707, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 708-720, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 728-733, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 734-739, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 721-724, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 725-727, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 740-741, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 742-743, May 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 5, Page 744-745, May 2026. <br/>

When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in a mid-stage trial of advanced melanoma—a result analysts said could help “instill confidence” in the regimen.

In addition to eliciting 17.3 months median overall survival vs. 8.5 months for patients given standard of care treatment in a prior study, Immuneering’s atebimetinib demonstrated a robust tolerability profile—something CEO Ben Zeskind said equates highly with survival.

Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.

Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing both primary and secondary endpoints.

Analysts are extremely encouraged by Phase 2 trial results for Relay Therapeutics’ PI3KA inhibitor in treating vascular malformations (VM), prompting the biotech to eye a potential path to accelerated approval.

While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted biomarker and cognitive improvements from the Phase 2 study, leaving analysts eager for more data.

Entrada Therapeutics saw a 2.36% dystrophin increase in patients treated with its oligonucleotide asset—a number that fell short of the company’s prior guidance of a double-digit improvement.

Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its potentially first-in-class oral treatment this year.

Johnson & Johnson plans to advance the co-antibody therapy, which combines its IL-23 blocker Tremfya and the TNF-alpha inhibitor Simponi, into late-stage testing for Crohn’s disease and ulcerative colitis.

Corcept Therapeutics’ amyotrophic lateral sclerosis drug was linked to an 87% reduction in the risk of death, a result the biotech hopes to replicate in an upcoming Phase 3 trial.

In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in patients with diffuse large B cell lymphoma, casting doubt on its value as a second-line treatment in this indication.

Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast cancer. Still, the biotech’s stock dropped more than 25% Tuesday.

Merck may not have had the splashiest presentation at the American Society of Clinical Oncology meeting, but the data show why the Big Pharma remains king of oncology, analysts say.

Interim overall survival data on a TROP2 ADC from Merck and Chinese partner Kelun-Biotech provide support for the pharma’s big bet on its potential to help navigate Keytruda’s impending loss of exclusivity.

Revolution Medicines and its RAS inhibitor daraxonrasib stole the show at the American Society of Clinical Oncology’s annual meeting this weekend, as Truist Securities predicts a possible third quarter launch for the pancreatic cancer drug.

Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous data from Akeso’s HARMONi-6 trial left them wanting.

As Summit Therapeutics’ Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.

The antisense oligonucleotide was even more effective in patients with relatively low viral activity. More than one-quarter of these individuals had undetectable levels of the virus in the blood for at least six months after stopping treatment.

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.

After being hit by safety issues and subpar results in another trial, BioMarin’s Phase 3 test of Voxzogo for a rare skeletal disorder called hypochondroplasia showed efficacy “solidly above” what the drug has shown for achondroplasia, which causes dwarfism.

By inhibiting the APRIL cascade, Otsuka Pharmaceuticals’ Voyxact slowed kidney function decline in patients with IgAN, opening up a potential path for full approval while also reading through to Vertex and others with similar assets.

In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in patients with diffuse large B cell lymphoma, casting doubt on its value as a second-line treatment in this indication.

In this episode of Denatured, you’ll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli Lilly. We dive into the long-overlooked hair loss space, exploring why true innovation has lagged, how a regenerative approach aims to reactivate dormant follicles and what early proof-of-concept means for patients.

Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast cancer. Still, the biotech’s stock dropped more than 25% Tuesday.

All six non-Hodgkin lymphoma patients on Legend Biotech’s CAR T therapy responded to treatment—findings that could make the biotech an attractive takeover target, according to analysts at Oppenheimer.

Improved survival on display at the American Society of Clinical Oncology (ASCO) in Chicago; Pfizer’s unusual pact with China’s Innovent highlights a new type of collaboration; Eli Lilly continues its nonstop deal streak, including with Chinese biotechs; and looking ahead to this weekend’s American Diabetes Association meeting.

Merck may not have had the splashiest presentation at the American Society of Clinical Oncology meeting, but the data show why the Big Pharma remains king of oncology, analysts say.

When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in a mid-stage trial of advanced melanoma—a result analysts said could help “instill confidence” in the regimen.

Government backing, deep scientific talent and a robust pharma heritage are helping France punch above its weight, but turning research into investable companies remains a challenge.

In addition to eliciting 17.3 months median overall survival vs. 8.5 months for patients given standard of care treatment in a prior study, Immuneering’s atebimetinib demonstrated a robust tolerability profile—something CEO Ben Zeskind said equates highly with survival.

On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).

On May 27, 2026, the Food and Drug Administration approved pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

On May 22, 2026, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.

On May 15, 2026, the Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu, Daiichi Sankyo, Inc.) for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for T-DXd followed by a taxane, trastuzumab, and pertuzumab (THP), for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test. The second indication is for T-DXd for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab (with or without pertuzumab) and taxane-based treatment.

On May 15, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc. and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.

On May 13, 2026, the Food and Drug Administration approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.

On May 13, 2026, the Food and Drug Administration granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.

On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.

On May 1, 2026, the Food and Drug Administration approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. 

On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.

On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).

On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. 

On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.

On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024. 

On February 19, 2026, the Food and Drug Administration approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

On February 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.

On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.). See the prescribing information for the specific indications.

On December 17, 2025, the Food and Drug Administration approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic (CDx).

On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer as determined by an FDA-approved test.

On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC), as determined by an FDA-approved test.

On December 4, 2025, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company) for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy

On December 3, 2025, the Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

N Engl J Med. 2026 May 31. doi: 10.1056/NEJMoa2605555.
O'Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, Hammel P, Cremolini C, Manji GA, Oberstein PE, Garrido-Laguna I, Springfeld C, Azad NS, Ueno M, Chui SY, Zhang Y, Patel H, Lee Y, Salman Z, Wolpin BM; RASolute 302 Trial Investigators

Lancet Infect Dis. 2026 Jun 2:S1473-3099(26)00194-5. doi: 10.1016/S1473-3099(26)00194-5.
GBD 2023 Diarrhoeal Disease and Enteric Infectious Diseases Collaborators

Thyroid. 2026 May;36(5):481-544. doi: 10.1177/10507256261445624. Epub 2026 May 31.
Korevaar TIM, Leung AM, Alexander EK, Bliddal S, Boelaert K, Brenta G, Chou R, Dhillon-Smith R, Dosiou C, Eaton JL, Guan H, Kilpatrick SJ, Lasserre BJ, Lee SY, Maraka S, Meister KD, Morris-Wiseman LF, Nguyen CT, Pearce EN, Shan Z

N Engl J Med. 2026 May 31. doi: 10.1056/NEJMoa2603878.
Taplin ME, Gleave M, Shore ND, Lopez-Gitlitz A, Kretschmer A, Efstathiou E, Nguyen PL, Damião R, Kamoto T, Ross A, Briganti A, Hadaschik BA, Heidenreich A, Juárez Soto Á, Ye H, Gotto G, Rooney B, Tian SK, Wetherhold L, Miladinovic B, McCarthy SA, Evans CP, Kibel AS; PROTEUS Investigators

Lancet. 2026 May 31:S0140-6736(26)00966-9. doi: 10.1016/S0140-6736(26)00966-9.
Lu S, Liu B, Luo Y, Sun L, Wu L, Han Z, Fan Y, Zhao Y, Li X, Xu H, Meng X, Liu Y, Zhang Z, Luo H, Ma X, Ma X, Shi Q, Zhang Z, Yang R, Wang P, Pan P, Ai X, Li J, Pu X, Wang Z, Fang J, He M, He Y, Guo S, Li J, Wang H, Zhang J, Chu Q, Liu X, Ying S, Wu H, Sun H, Ji Y, Zhou M, Cao C, Tang K, Li Z, Li D, Zhang Z, Li J, Zhou J, Yang H, Du Y, Yang H, Shi J, Chen H, Chen Z, Li W, Lu D, Hu M, Wang ZM, Li B, Xia MY

Lancet. 1991 Sep 28;338(8770):798-800. doi: 10.1016/0140-6736(91)90676-g.
Abd-el-Maeboud KH, el-Naggar T, el-Hawi EM, Mahmoud SA, Abd-el-Hay S

J Laryngol Otol. 2026 Jun 1:1-18. doi: 10.1017/S0022215126104988.
Zaidi AK, Mohanarajah NT, Ahmed SK; Consultants at UHB for Research & Excellence in ENT

Science. 2026 May 28;392(6801):eadz2742. doi: 10.1126/science.adz2742. Epub 2026 May 28.
Cho KS, Liu Y, Pei G, Chen J, Dai Y, Liu Y, Zhou T, Bougouin A, Serrano A, Wani K, Jadhav A, Min J, Hernandez S, Lu W, Zhang D, Jiang J, Shamsutdinova D, Dai E, Peng F, Sinjab A, Guerrero PA, Julio ICL, Yu K, Clark H, Maru D, Li M, Futreal A, Lee S, Solis Soto LM, Shang L, Msaouel P, Ajani JA, Beird H, Jazaeri AA, Lazar AJ, Sautes-Fridman C, Fridman WH, Maitra A, Kadara H, Gao J, Sharma P, Wang L

Proc Natl Acad Sci U S A. 2026 Jun 9;123(23):e2610708123. doi: 10.1073/pnas.2610708123. Epub 2026 Jun 1.
Liaki V, Barrambana S, Kostopoulou M, Lechuga CG, Zamorano-Dominguez E, Acosta-Gallego D, Morales-Cacho L, Álvarez R, Sun P, Rosas-Perez B, Barrero R, Jiménez-Parrado S, López-García A, San Roman M, López-Gil JC, Drosten M, Sainz B Jr, Musteanu M, Caleiras E, Dusetti N, Poli V, Sánchez-Bueno F, Guerra C, Barbacid M

BMJ Case Rep. 2019 Mar 8;12(3):e227398. doi: 10.1136/bcr-2018-227398.
Gómez Caballero N, Almenara S, Tévar Terol A, Horga de la Parte JF

Bone Jt Open. 2026 Jun 1;7(6):713-723. doi: 10.1302/2633-1462.76.BJO-2026-0037.R1.
Smolle MA, Wenzl FA, Laitinen MK, Jeys LM; BOOM Consortium; Leithner A, Abdul Bari Y, Abood A, Abraham J, Acosta M, Agarwal R, Agarwal M, Ajit Singh V, Akiyama T, Al Farii H, Aldosari Omar A, Alfaro P, Aljuhani W, Allison D, Almashahedi M, Alotaibi A, Alpan B, Alshaygy Ibrahim S, Althunayan T, Andreani L, Andreou D, Andriandi A, Annabell L, Aponte-Tinao L, Armas S, Aston W, Aycan Osman E, Baad-Hansen T, Baird C, Balach T, Barriga Juan A, Barry J, Basile G, Bastoni S, Basuki Mohammad H, Bauer H, Bayliss L, Becker R, Bedi A, Benevenia J, Bengoa F, Berger C, Bernthal N, Binitie O, Bird JE, Bobseit A, Bodian C, Boffano M, Bonilla Huertas P, Botello E, Boyle R, Bramer J, Broekhuis D, Broida SE, Brown D, Budny T, Burke Z, Cabrolier J, Calvo Haro Jose A, Campanacci DA, Cardoso R, Carey Smith R, Casales Fresenga N, Ceballos O, Chan Chung M, Chan L, Choong P, Chrobok A, Chung YG, Ciechanowicz D, Clara-Altamirano Miguel A, Consuegra L, Courtot L, Crawford B, Cribb G, Cuervo-Lozano Carlos E, Dammerer D, de la Rosa P, De Paolis M, De Santos de la Fuente Francisco J, de Vaal M, Deisenhofer J, Delgado J, Deo S, Deventer N, Di Bella C, Dierselhuis E, Domson G, Donati DM, Duran-Ciarrochi R, Durr … See abstract for full author list ➔ Smolle MA, et al

N Engl J Med. 2026 May 31. doi: 10.1056/NEJMoa2602628.
Wu YL, Hochmair M, Yang Y, Yang XN, Tsuboi M, Paz-Ares L, Yang JC, Wu L, Kim HR, Rieke DT, Johnson M, Besse B, Sharma N, Maeda P, Peterson P, Lin BK, Frimodt-Moller B, Goldman J, Drilon A; LIBRETTO-432 Trial Investigators

Nat Cell Biol. 2026 Jun 1. doi: 10.1038/s41556-026-01972-2.
Argenziano MG, Neelakantan TV, Sperring C, Adeuyan O, Higgins DMO, Bruce JN, Kim BYS, Dovas A, Canoll P, Lim M, Stockwell BR, Banu MA

N Engl J Med. 2000 Nov 23;343(21):1506-13. doi: 10.1056/NEJM200011233432101.
Kannus P, Parkkari J, Niemi S, Pasanen M, Palvanen M, Järvinen M, Vuori I

N Engl J Med. 2026 May 28. doi: 10.1056/NEJMoa2515131.
Hou J, Lim SG, Buti M, Yuen MF, Gane E, Lampertico P, Terrault N, Nguyen H, Yim HJ, Xie Q, Lin J, Qiu Y, Jeng WJ, Heo J, Peng CY, Chen CH, Chuang WL, Xie Y, Hlebowicz M, Idriz N, Mehta R, Agarwal K, Gomes da Silva MM, Franca A, Cernat R, Leerapun A, Coffin CS, Gadano A, Andreone P, Fujiyama S, Sevastianos V, Suzuki Y, Ratziu V, Riachi G, Stocker H, Lim TH, Asselah T, Tanaka Y, Holmes J, Liang X, Cremer J, Lukić T, Plein H, Quinn G, Tao Y, Paff M, Theodore D, Elston R; B-Well Study Group

Lancet. 2026 May 30:S0140-6736(26)00866-4. doi: 10.1016/S0140-6736(26)00866-4.
Lenz G, Trněný M, Burke JM, Nowakowski GS, Fox CP, Chiappella A, Duell J, Jeon YW, Cheah CY, Westin J, Ye JZ, Caguioa PB, Belada D, Shin HJ, Oh SY, Amorim S, Ku M, Mocikova H, Jiménez JL, Gaidano G, Rosenwald A, Chiarle R, Colucci P, Ioannidis S, Cheng L, Vitolo U; frontMIND Study Investigators

J Clin Oncol. 2026 May 31:101200JCO2601042. doi: 10.1200/JCO-26-01042.
Burtness B, Rosenberg AJ, Calderon B, Lim SM, Yang MH, Li SH, Kadowaki S, Swiecicki PL, Geiger JL, Ince W, Hahn D, Guo Y, Adkins D, Metcalf R, Ahn MJ, Sukari A, Braña I, Keam B, Tanaka H, Sheth S, Oliva M, Lyu X, Curtin JC, Toyoizumi K, Xie J, Wade M, Diorio B, Kapoor A, Yilmaz E, Baig M, Kim P, Verheijen RB, Shah S, Harrington KJ

N Engl J Med. 2026 May 29. doi: 10.1056/NEJMoa2603870.
Touzeau C, Mina R, Quach H, Hungria V, Bhutani D, Chen W, Kumar S, Chaulagain C, Dimopoulos MA, Bahlis NJ, Maral S, van de Donk NWCJ, Schmidt Filho J, Saja K, Teipel R, Ando M, Roeloffzen W, Annibali O, Augustson B, Botta C, Delforge M, Bourgeois E, Buda G, Hus M, Perrot A, Preis M, Beksac M, Pour L, Farmer S, Nunes M, Oriol A, Melchardt T, Hu Y, Flogegård M, Wang D, Pei L, Wroblewski S, Ariës IM, Quijano Cardé NA, Perova T, de Jager T, Yeh TM, Vanquickelberghe V, Shah P, Chastain K, Kobos R, Carson R, Landgren O; MajesTEC-9 Trial Investigators

Anticancer Res. 2026 Jun;46(6):3243-3255. doi: 10.21873/anticanres.18194.
Hulscher N, Victory K, Thorp JA, Pinsky D, Diaz-Villalobos A, Gillooly P, Coulson F, Annazone M, Radesi C, Brooks J, McCULLOUGH PA, Risch H

N Engl J Med. 2026 May 30. doi: 10.1056/NEJMoa2604126.
Agarwal N, Matsubara N, Azad AA, Saad F, Mateo J, Jiang S, Ye D, Voog E, Shore ND, Çil T, Vulsteke C, Chung HJ, Zschäbitz S, Laird AD, Zhang X, Nandoskar P, Chetcuti SF, Wang F, Fizazi K